
Our mission is to develop disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases to address the unmet medical need.
-
Highlight
View Full Year 2024 report webinar
-
Highlight
Herantis Pharma has successfully completed the Part 1 of the Phase 1b clinical trial
-
Highlight
Herantis Pharma receives research funding from The Michael J. Fox Foundation, US and the Parkinson's Virtual Biotech, UK